ATE476993T1 - Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko - Google Patents

Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko

Info

Publication number
ATE476993T1
ATE476993T1 AT05756588T AT05756588T ATE476993T1 AT E476993 T1 ATE476993 T1 AT E476993T1 AT 05756588 T AT05756588 T AT 05756588T AT 05756588 T AT05756588 T AT 05756588T AT E476993 T1 ATE476993 T1 AT E476993T1
Authority
AT
Austria
Prior art keywords
disease
neur
inflammation
reduced risk
amyloid aggregation
Prior art date
Application number
AT05756588T
Other languages
English (en)
Inventor
Beka Solomon
Sabina Rebe
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35503668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE476993(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE476993T1 publication Critical patent/ATE476993T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05756588T 2004-06-07 2005-06-06 Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko ATE476993T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57720204P 2004-06-07 2004-06-07
PCT/US2005/019617 WO2005120571A2 (en) 2004-06-07 2005-06-06 Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation

Publications (1)

Publication Number Publication Date
ATE476993T1 true ATE476993T1 (de) 2010-08-15

Family

ID=35503668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05756588T ATE476993T1 (de) 2004-06-07 2005-06-06 Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko

Country Status (5)

Country Link
US (1) US20110142858A1 (de)
EP (1) EP1766396B1 (de)
AT (1) ATE476993T1 (de)
DE (1) DE602005022871D1 (de)
WO (1) WO2005120571A2 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP5042828B2 (ja) * 2004-07-30 2012-10-03 ライナット ニューロサイエンス コーポレイション アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
SG10201402712QA (en) 2005-08-31 2014-08-28 Merck Sharp & Dohme Engineered anti-il-23 antibodies
JP2009507023A (ja) 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
ES2527661T3 (es) 2005-11-30 2015-01-28 Abbvie Inc. Método de exploración, proceso para purificar oligómeros Abeta no difundibles, anticuerpos selectivos contra dichos oligómeros Abeta no difundibles y un proceso para fabricar dichos anticuerpos
KR101605207B1 (ko) 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CA2671538A1 (en) 2006-12-14 2008-06-26 Leonard G. Presta Engineered anti-tslp antibody
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
AU2008203703C1 (en) 2007-01-05 2014-04-03 University Of Zurich Method of providing disease-specific binding molecules and targets
RS58098B1 (sr) 2007-02-23 2019-02-28 Merck Sharp & Dohme Anti-il-23p19 antitela proizvedena genetičkim inženjerstvom
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
EP2417974A1 (de) 2007-02-28 2012-02-15 Schering Corporation Kombinationstherapie zur Behandlung von Immunerkrankungen
CA2679381A1 (en) 2007-02-28 2008-09-04 Schering Corporation Engineered anti-il-23r antibodies
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (de) 2007-04-18 2014-12-24 Probiodrug AG Thioharnstoffderivate als glutaminylcyclaseinhibitoren
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2238166B1 (de) 2007-10-05 2013-11-27 Genentech, Inc. Verwendung eines anti-amyloid-beta-antikörpers bei augenkrankheiten
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
MX2011006549A (es) 2008-12-19 2011-07-20 Schering Corp Suplemento alimenticio para el cultivo de celula de mamifero y metodos de uso.
PT2403528E (pt) 2009-03-02 2016-06-08 Aduro Biotech Holdings Europe B V Anticorpos contra um ligando indutor da proliferação (april)
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
WO2011014438A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
ES2788869T3 (es) 2009-09-03 2020-10-23 Merck Sharp & Dohme Anticuerpos anti-GITR
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2496707B1 (de) 2009-11-04 2020-02-26 Merck Sharp & Dohme Corp. Entwickelter antikörper gegen tslp
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
EP2542549B1 (de) 2010-03-03 2016-05-11 Probiodrug AG Glutaminylcyclase-hemmer
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
CN102933601B (zh) 2010-04-15 2016-06-08 Abbvie公司 β淀粉样蛋白结合蛋白
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
JP6023706B2 (ja) 2010-07-09 2016-11-09 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ２７に対するアゴニスト抗体
EP2598882B1 (de) 2010-07-30 2017-07-26 AC Immune S.A. Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
PT2723379T (pt) 2011-06-23 2018-11-14 Univ Of Zuerich Moléculas de ligação anti-alfa-sinucleína
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CA2917858A1 (en) 2013-08-02 2015-02-05 Aduro Biotech Holdings, Europe B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
CA2921639A1 (en) 2013-09-05 2015-03-12 Aduro Biotech Holdings, Europe B.V. Cd70-binding peptides and method, process and use relating thereto
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
KR20160092024A (ko) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
KR102321168B1 (ko) 2014-08-19 2021-11-02 머크 샤프 앤드 돔 코포레이션 항-tigit 항체
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EP3399989B1 (de) 2015-12-16 2023-08-09 Merck Sharp & Dohme LLC Anti-lag3-antikörper und antigenbindende fragmente
EP3445393B1 (de) 2016-04-20 2026-01-14 Merck Sharp & Dohme LLC Cmv-neutralisierende antigenbindende proteine
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20200041A1 (ar) 2017-08-22 2020-02-20 Biogen Ma Inc تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN109970857B (zh) 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
JP7534303B2 (ja) 2018-09-13 2024-08-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 新規のｌｉｌｒｂ４抗体およびその使用
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
JP7475341B2 (ja) 2018-10-31 2024-04-26 メルク・シャープ・アンド・ドーム・エルエルシー 抗ヒトｐｄ－１抗体結晶およびその使用方法
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
BR112022012075A2 (pt) 2019-12-17 2022-08-30 Chinook Therapeutics Inc Métodos para tratar nefropatia por iga com atrasentan
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
IL297806A (en) 2020-04-30 2022-12-01 Sairopa B V Anti-cd103 antibodies
US20230265175A1 (en) 2020-06-25 2023-08-24 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
EP4217394A1 (de) 2020-09-24 2023-08-02 Merck Sharp & Dohme LLC Stabile formulierungen von programmiert-tod-rezeptor-1-antikörpern und hyaluronidase-varianten und fragmenten davon sowie verfahren zur verwendung davon
EP4255451A4 (de) 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Verfahren zur identifizierung von lilrb-blockierenden antikörpern
WO2022165001A1 (en) 2021-01-29 2022-08-04 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
AU2023366516A1 (en) 2022-10-28 2025-05-15 Aduro Biotech Holdings, Europe B.V. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
TW202539744A (zh) 2024-02-27 2025-10-16 美商必治妥美雅史谷比公司 抗ｃｅａｃａｍ５抗體藥物軛合物
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3655899A (en) * 1998-04-20 1999-11-08 Regents Of The University Of California, The Modified immunoglobulin molecules and methods for use thereof
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
DK1944040T3 (da) * 2001-08-17 2012-10-29 Univ Washington Analysefremgangsmåde for Alzheimers sygdom
US20040192898A1 (en) * 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
EP1429805A4 (de) * 2001-08-17 2005-09-21 Lilly Co Eli Verwendung von antikörpern mit hoher affinität für lösliche ass zur behandlung von zuständen und erkrankungen im zusammenhang mit ass
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20070134247A9 (en) * 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
WO2003101485A1 (en) * 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
CA2536408A1 (en) * 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same

Also Published As

Publication number Publication date
EP1766396A4 (de) 2007-06-20
EP1766396A2 (de) 2007-03-28
DE602005022871D1 (de) 2010-09-23
US20110142858A1 (en) 2011-06-16
EP1766396B1 (de) 2010-08-11
WO2005120571A3 (en) 2006-08-24
WO2005120571A2 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
ATE476993T1 (de) Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
CL2020001619A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional solicitud 201903095)
EP3782058A4 (de) Dezentralisierte maschine zur überprüfung von dokumenten und entitäten
ATE537190T1 (de) Hochaffine antikörper gegen den humanen il-6- rezeptor
EA200870130A1 (ru) Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
EP2394658A3 (de) Passive Immunisierung gegen Clostridium difficile-Erkrankung
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
RU2016151179A (ru) Ornithodoros moubata игибитор комплемента, предназначенный для лечения опосредованных комплементом заболеваний пациента с полиморфизмом с5 комплемента
ATE423571T1 (de) Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
WO2007056457A3 (en) Methods, compositions, and kits for the treatment of medical conditions
DK2371391T3 (da) Terapeutisk anvendelse af anti-CS1-antistoffer
BRPI0916138A2 (pt) "método de tratamento de um sujeito diagnosticado com câncer de mama localmente, kit para tratar câncer de mama metastático em um sujeito humano, uso de um anticorpo antivegf na fabricação de um medicamento para tratar câncer de mama localmente recidivado ou metastático em um sujeito e anticorpo anti-vegf para uso em um método de tratamento de câncer de mama localmente recidivado ou metastático em um sujeito"
EP2484537A3 (de) Authentizitätssicherung von Wertdokumenten mittels photochromer Farbstoffe
AR048888A1 (es) Prevencion de una enfermedad autoinmune
BR112014025768A2 (pt) métodos de tratamento de espondilite anquilosante usando antagonistas de il-17
WO2014194274A3 (en) Oncostatin m receptor antigen binding proteins
RU2011142183A (ru) Средство для лечения ревматоидного артрита
ATE517601T1 (de) Multifunktionales gerät für personen mit beeinträchtigtem sehvermögen
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
BRPI0512500A (pt) tratamento ou condições envolvendo desmielinação
EP4149977A4 (de) Anti-il13r-alpha-2-antikörper, antigenbindende fragmente und verwendungen davon
DE602005014312D1 (de) Bauelement zur Detektion elektromagnetischer Strahlung, insbesondere Infrarot, optische Baugruppe für Infrarotabbildung mit integriertem solchen Bauelement und dessen Herstellungsverfahren
EP3444466A4 (de) Ventilkörper, elektronisch gesteuerte drosselklappe, motorgetriebene drosselklappe und ventilvorrichtung
EP4010826A4 (de) Vergleich von biometrischen kennungen in einem speicher

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties